Therefore, the design of multitarget compounds based on AD physiopathology involved compounds that inhibit AChE, an enzyme responsible to hydrolyze the acetylcholine neurotransmitter (ACh) and related to cholinergic hypothesis. The gene discussed is ACHE; the disease is Alzheimer disease.